| Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group C Fernández de Larrea, RA Kyle, BGM Durie, H Ludwig, S Usmani, ... Leukemia 27 (4), 780-791, 2013 | 429 | 2013 |
| A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study CS Tam, S Opat, S D'Sa, W Jurczak, HP Lee, G Cull, RG Owen, P Marlton, ... Blood, The Journal of the American Society of Hematology 136 (18), 2038-2050, 2020 | 403 | 2020 |
| GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells EL Smith, K Harrington, M Staehr, R Masakayan, J Jones, TJ Long, KY Ng, ... Science translational medicine 11 (485), eaau7746, 2019 | 319 | 2019 |
| Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial MA Dimopoulos, J Trotman, A Tedeschi, JV Matous, D Macdonald, C Tam, ... The Lancet Oncology 18 (2), 241-250, 2017 | 241 | 2017 |
| A practical approach to the diagnosis of systemic amyloidoses C Fernández de Larrea, L Verga, P Morbini, C Klersy, F Lavatelli, A Foli, ... Blood, The Journal of the American Society of Hematology 125 (14), 2239-2244, 2015 | 216 | 2015 |
| International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) MV Mateos, S Kumar, MA Dimopoulos, V González-Calle, E Kastritis, ... Blood cancer journal 10 (10), 102, 2020 | 185 | 2020 |
| Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape–driven relapse in multiple myeloma C Fernández de Larrea, M Staehr, AV Lopez, KY Ng, Y Chen, ... Blood cancer discovery 1 (2), 146-154, 2020 | 154* | 2020 |
| Extramedullary involvement in multiple myeloma J Bladé, CF de Larrea, L Rosiñol Haematologica 97 (11), 1618, 2012 | 132 | 2012 |
| Pathogenesis and progression of monoclonal gammopathy of undetermined significance J Blade, L Rosinol, MT Cibeira, CF de Larrea Leukemia 22 (9), 1651-1657, 2008 | 128 | 2008 |
| Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition M Granell, X Calvo, A Garcia-Guiñón, L Escoda, E Abella, CM Martínez, ... Haematologica 102 (6), 1099, 2017 | 118 | 2017 |
| Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations L Rosiñol, M Beksac, E Zamagni, NWCJ Van de Donk, KC Anderson, ... British journal of haematology 194 (3), 496-507, 2021 | 109 | 2021 |
| Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center E Carreras, F Fernández-Avilés, L Silva, M Guerrero, CF De Larrea, ... Bone marrow transplantation 45 (9), 1417-1422, 2010 | 108 | 2010 |
| Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed/refractory multiple myeloma: final results of a phase I … S Mailankody, A Ghosh, M Staehr, TJ Purdon, M Roshal, E Halton, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 88 | 2018 |
| Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for … CF de Larrea, MT Cibeira, M Elena, JI Arostegui, L Rosiñol, M Rovira, ... Blood, The Journal of the American Society of Hematology 114 (24), 4954-4956, 2009 | 83 | 2009 |
| CAR T-cells in multiple myeloma: state of the art and future directions LG Rodríguez-Lobato, M Ganzetti, C Fernandez de Larrea, M Hudecek, ... Frontiers in Oncology 10, 1243, 2020 | 78 | 2020 |
| Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality J Martínez-López, MV Mateos, C Encinas, A Sureda, JÁ Hernández-Rivas, ... Blood cancer journal 10 (10), 103, 2020 | 77 | 2020 |
| Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation CF de Larrea, A Navarro, R Tejero, N Tovar, T Díaz, MT Cibeira, L Rosinol, ... Clinical cancer research 18 (13), 3697-3704, 2012 | 72 | 2012 |
| Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression C Fernandez de Larrea, I Isola, A Pereira, MT Cibeira, L Magnano, ... Leukemia 32 (6), 1427-1434, 2018 | 65 | 2018 |
| iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia … MA Dimopoulos, J Trotman, A Tedeschi, JV Matous, D Macdonald, C Tam, ... Lancet Oncol 18 (2), 241-250, 2017 | 65 | 2017 |
| Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a … N Tovar, CF de Larrea, JI Aróstegui, MT Cibeira, L Rosiñol, M Rovira, ... haematologica 98 (7), 1142, 2013 | 60 | 2013 |
